講師
Date:27 July (Thursday)
Time:10:40 – 12:10 (GMT+8)
Chief Executive Officer
TaiMed Biologics Inc
Dr. Chin-Ming Chang is a distinguished thought leader and expert in the field of biotechnology and pharmaceuticals, recognized for his significant contributions to the development and commercialization of innovative therapies targeting various medical conditions such as infectious diseases, ophthalmology, Alzheimer's disease, and osteoporosis. Currently serving as the CEO of TaiMed Biologics, Dr. Chang leads the company in its mission to pioneer groundbreaking treatments for HIV.
Driven by a desire to save lives and combat diseases. Dr. Chang displayed a deep interest in the field of pharmaceuticals since young. He completed his undergraduate studies at the National Taiwan University, where he earned a B.S. in Pharmacy. Building upon his foundational knowledge, Dr. Chang pursued advanced studies and obtained a Ph.D. in Pharmaceutics from the University of Texas at Austin.
Following the completion of his education, Dr. Chang embarked on a fruitful career in the biotechnology industry. He gained invaluable experience and expertise through various scientific and leadership roles at esteemed companies such as Eli Lilly and Allergan. Eventually, his remarkable skills and knowledge led him to join TaiMed Biologics, where he swiftly ascended through the ranks and become the CEO.
Dr. Chang's visionary mindset and unwavering commitment to scientific excellence have played a pivotal role in establishing TaiMed as a prominent player within the biopharmaceutical industry. Under his guidance, TaiMed achieved remarkable milestones, notably the successful commercialization of Trogarzo, the world's first and only monoclonal antibody (mAb)-based drug product for the treatment of multi-drug resistant HIV patients. Trogarzo has provided renewed hope and improved health outcomes for individuals battling this challenging condition.
Continuing his pursuit of innovation, Dr. Chang spearheads TaiMed’s efforts to develop the world's first and only mAb-based long-acting combination therapy for HIV. This groundbreaking therapy holds tremendous potential to revolutionize HIV treatment and improve the lives of countless individuals affected by the disease.
Over the past five years, Dr. Chang has played a crucial role in driving the advancement of TaiMed's research and development pipeline, overseeing the successful commercialization of Trogarzo, and leading the establishment of their GMP manufacturing facility and CDMO services. His exceptional leadership and scientific acumen continue to shape the trajectory of TaiMed Biologics, positioning the company at the forefront of biopharmaceutical innovation and healthcare advancement.
Overall, Dr. Chin-Ming Chang's remarkable contributions, visionary approach, and dedication to scientific excellence have solidified his reputation as a key thought leader in the biotechnology and pharmaceutical fields. His transformative work at TaiMed Biologics reflects his unwavering commitment to developing innovative therapies that have the potential to transform the lives of patients worldwide.